Satya Das, MD, MSCI, on the Impact of PRRT in Patients With Well-Differentiated NETs
The expert in hematology/oncology discussed the implications of a study which evaluated the use of peptide receptor radionuclide therapy in patients with well-differentiated neuroendocrine tumors.
Martha Ann Raymond, MA, on What Providers Should Do to Enhance Clinical Trial Participation in the COVID-19 Era
The founding executive director of the GI Cancers Alliance discussed important takeaways from a study of patient perspectives of clinical trial participation during the COVID-19 pandemic.
Aung Naing, MD, Discusses Strategies for the Effective Management of IRAEs
The increasing use of checkpoint inhibitors and other immunotherapies has created a need for the development of a cohesive education program and list of guidelines for treating common toxicities.
Kelley Lauren Coffman, MD, Responses to and Adverse Effects of Therapy With 177Lu-DOTATATE in Well-Differentiated, High-Grade NETs
The hospitalist at Memorial Sloan Kettering Cancer Center discussed the results of a study which evaluated the use of 177Lu-DOTATATE in patients with well-differentiated, high-grade neuroendocrine tumors.
Satya Das, MD, MSCI, on the Use of PRRT in Patients With Well-Differentiated NETs
The expert in hematology/oncology discussed the results of a study which evaluated the use of peptide receptor radionuclide therapy in patients with well-differentiated neuroendocrine tumors.
Reid Merryman, MD, on Potential Clinical Designs with MRD-Guidance for Patients with DLBCL
Expert details the potential for a clinical trial using minimal residual disease to guide therapy for patients with DLBCL.
Kevin Kalinsky, MD, MS, on Exciting Breast Cancer Treatments Coming Down the Pike
“We’re hearing about other antibody-drug conjugates, other agents in hormone receptor–positive metastatic disease, and the next generation of drugs that we’ll be using to treat our patients.”
Reid Merryman, MD, on Pre- and Post-Transplant Data for Patients with DLBCL
Merryman explains the value of evaluating separate transplant-related questions for patients with relapsed or refractory diffuse large B-cell lymphoma.
Deepu Madduri, MD, on Research in Multiple Myeloma This Past Year
The expert in multiple myeloma spoke about the research that she believes will be most influential for patients with multiple myeloma.
Dan Pollyea, MD, MS, on Venetoclax and IDH Mutations in Patients With AML
The leukemia expert talks about how current findings may hold promise for a larger group of patients in the future.
Reid Merryman, MD, on Study Findings Investigating Prognostic Value of ctDNA for Patients with DLBCL
Thought leader detailed the findings from an oral presentation investigating patients with relapsed or refractory diffuse large B-cell lymphoma.
Deepu Madduri, MD, on the Future Potential of Therapies to Treat Multiple Myeloma
The expert in multiple myeloma highlighted the research which she was most excited to see presented at the ASH Annual Meeting & Exposition.
Kevin Kalinsky, MD, MS, on Next Steps Following the Phase 3 RxPONDER Trial
Investigators aimed to evaluate additional end points from the phase 3 RxPONDER trial in women with hormone receptor–positive, HER2-negative, lymph node–positive breast cancer.
Smoldering Multiple Myeloma
Future Directions for Treatment of Ovarian Cancer
Role of PARP Inhibition in Recurrent Ovarian Cancer
Selecting Maintenance Therapy in Ovarian Cancer
PAOLA-1 Trial
PRIMA Trial
SOLO-1 Trial
